EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer

2019/12/20 by Rebecca C. Arend, Allison M. Davis, Przemyslaw Chimiczewski +6
Medicine · Biochemistry, Genetics and Molecular Biology · #Ovarian cancer diagnosis and treatment #PARP inhibition in cancer therapy #PI3K/AKT/mTOR signaling in cancer

paper · doi:10.1016/j.ygyno.2019.12.002

Citations

• The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology